|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
123,030,000 |
Market
Cap: |
18.51(B) |
Last
Volume: |
856,179 |
Avg
Vol: |
722,222 |
52
Week Range: |
$143.31 - $211.65 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 824 |
Guru Rank Value : 0.5 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Alnylam Pharmaceuticals is a commercial-stage biopharmaceutical company developing therapeutics based on RNA interference. Co. has four RNAi-based medicines, ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO (lumasiran) and Leqvio® (inclisiran). ONPATTRO is approved for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. GIVLAARI is approved for the treatment of adults with acute hepatic porphyria. Co. has approval for OXLUMO for the treatment of hyperoxaluria type 1 (PH1) in all age groups. Leqvio (inclisiran) is being developed for the treatment of adults with hypercholesterolemia or mixed dyslipidemia.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
76,855 |
102,504 |
247,093 |
Total Sell Value |
$0 |
$12,957,715 |
$17,713,340 |
$48,829,179 |
Total People Sold |
0 |
7 |
8 |
9 |
Total Sell Transactions |
0 |
12 |
18 |
35 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Garg Pushkal |
CMO & EVP Dev & Med Affairs |
|
2022-08-04 |
4 |
D |
$189.76 |
$974,201 |
D/D |
(5,086) |
17,417 |
|
- |
|
Vaishnaw Akshay |
President |
|
2022-08-04 |
4 |
D |
$189.76 |
$1,160,335 |
D/D |
(6,052) |
18,346 |
|
- |
|
Poulton Jeffrey V. |
EVP, Chief Financial Officer |
|
2022-08-04 |
4 |
D |
$189.76 |
$968,824 |
D/D |
(5,054) |
9,406 |
|
- |
|
Tanguler Tolga |
EVP, Chief Commercial Officer |
|
2022-08-04 |
4 |
D |
$189.76 |
$342,817 |
D/D |
(1,788) |
1,841 |
|
- |
|
Greenstreet Yvonne |
Chief Executive Officer |
|
2022-08-04 |
4 |
D |
$189.76 |
$1,150,439 |
D/D |
(6,002) |
20,995 |
|
- |
|
Garg Pushkal |
CMO & EVP Dev & Med Affairs |
|
2022-08-03 |
4 |
A |
$0.00 |
$0 |
D/D |
11,311 |
22,503 |
|
- |
|
Vaishnaw Akshay |
President |
|
2022-08-03 |
4 |
A |
$0.00 |
$0 |
D/D |
13,183 |
24,398 |
|
- |
|
Poulton Jeffrey V. |
EVP, Chief Financial Officer |
|
2022-08-03 |
4 |
A |
$0.00 |
$0 |
D/D |
11,325 |
14,460 |
|
- |
|
Tanguler Tolga |
EVP, Chief Commercial Officer |
|
2022-08-03 |
4 |
AS |
$210.00 |
$368,340 |
D/D |
(1,754) |
3,629 |
|
10% |
|
Tanguler Tolga |
EVP, Chief Commercial Officer |
|
2022-08-03 |
4 |
A |
$0.00 |
$0 |
D/D |
3,629 |
5,383 |
|
- |
|
Greenstreet Yvonne |
Chief Executive Officer |
|
2022-08-03 |
4 |
A |
$0.00 |
$0 |
D/D |
13,095 |
26,997 |
|
- |
|
Tanguler Tolga |
EVP, Chief Commercial Officer |
|
2022-07-05 |
4 |
AS |
$150.00 |
$263,100 |
D/D |
(1,754) |
1,754 |
|
44% |
|
Paul Steven M |
Director |
|
2022-04-01 |
4 |
AS |
$166.04 |
$2,560,371 |
D/D |
(15,000) |
1,000 |
|
36% |
|
Paul Steven M |
Director |
|
2022-04-01 |
4 |
OE |
$11.33 |
$169,950 |
D/D |
15,000 |
16,000 |
|
- |
|
Sharp Philip A |
Director |
|
2022-02-09 |
4 |
AS |
$150.00 |
$4,500,000 |
D/D |
(30,000) |
0 |
|
-8% |
|
Sharp Philip A |
Director |
|
2022-02-09 |
4 |
OE |
$11.33 |
$339,900 |
D/D |
30,000 |
30,000 |
|
- |
|
Tanguler Tolga |
EVP, Chief Commercial Officer |
|
2022-02-02 |
4 |
D |
$144.67 |
$219,609 |
D/D |
(1,518) |
3,508 |
|
- |
|
Tanguler Tolga |
EVP, Chief Commercial Officer |
|
2022-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,026 |
5,026 |
|
- |
|
Garg Pushkal |
CMO & EVP Dev & Med AffairsOff |
|
2021-12-31 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
681 |
|
-29% |
|
Garg Pushkal |
CMO & EVP Dev & Med AffairsOff |
|
2021-12-31 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
11,192 |
|
-29% |
|
Vaishnaw Akshay |
President, R&D |
|
2021-12-23 |
4 |
AS |
$186.22 |
$549,698 |
D/D |
(2,879) |
11,215 |
|
-26% |
|
Vaishnaw Akshay |
President, R&D |
|
2021-12-22 |
4 |
D |
$186.48 |
$479,690 |
D/D |
(2,538) |
14,094 |
|
- |
|
Maraganore John |
Chief Executive Officer |
|
2021-12-22 |
4 |
D |
$186.02 |
$1,254,077 |
D/D |
(6,636) |
227,663 |
|
- |
|
Greenstreet Yvonne |
President & COO |
|
2021-12-22 |
4 |
D |
$186.55 |
$479,699 |
D/D |
(2,538) |
13,902 |
|
- |
|
Vaishnaw Akshay |
President, R&D |
|
2021-12-21 |
4 |
A |
$0.00 |
$0 |
D/D |
5,417 |
16,632 |
|
- |
|
475 Records found
|
|
Page 4 of 19 |
|
|